AR060785A1 - METHOD FOR THE PROTECTION OF LANGERHANS ISLANDS CELLS AGAINST APOPTOSIS DURING THE PROCESS OF OBTAINING DONOR CELLS - Google Patents

METHOD FOR THE PROTECTION OF LANGERHANS ISLANDS CELLS AGAINST APOPTOSIS DURING THE PROCESS OF OBTAINING DONOR CELLS

Info

Publication number
AR060785A1
AR060785A1 ARP070101971A ARP070101971A AR060785A1 AR 060785 A1 AR060785 A1 AR 060785A1 AR P070101971 A ARP070101971 A AR P070101971A AR P070101971 A ARP070101971 A AR P070101971A AR 060785 A1 AR060785 A1 AR 060785A1
Authority
AR
Argentina
Prior art keywords
cells
eif5a
protection
apoptosis during
against apoptosis
Prior art date
Application number
ARP070101971A
Other languages
Spanish (es)
Inventor
Charles A Dinarello
John E Thomspon
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of AR060785A1 publication Critical patent/AR060785A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

Métodos para mejorar la viabilidad y recuperacion de islotes que se separan de un organo donante para su posterior transplante y más particularmente se relaciona con el uso de eIF5A de siARNs para aumentar la viabilidad de los islotes. Reivindicacion 1: Un método para inhibir las células de islotes que padecen de apoptosis durante el proceso de obtencion de donante que comprende administrar eIF5A siARN a las células de islotes de un donante de células de islotes antes del aislamiento del islote, caracterizado porque eIF5A de siARN inhibe la expresion de eIF5A en las células de islote y así inhibe la apoptosis en las células de islotes.Methods to improve the viability and recovery of islets that are separated from a donor organ for subsequent transplantation and more particularly related to the use of eIF5A of siRNAs to increase the viability of the islets. Claim 1: A method for inhibiting islet cells suffering from apoptosis during the donor process comprising administering eIF5A siRNA to the islet cells of an islet cell donor before islet isolation, characterized in that eIF5A of siRNA It inhibits the expression of eIF5A in islet cells and thus inhibits apoptosis in islet cells.

ARP070101971A 2006-03-20 2007-05-07 METHOD FOR THE PROTECTION OF LANGERHANS ISLANDS CELLS AGAINST APOPTOSIS DURING THE PROCESS OF OBTAINING DONOR CELLS AR060785A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78341406P 2006-03-20 2006-03-20
PCT/US2007/064424 WO2007109677A2 (en) 2006-03-20 2007-03-20 A novel method of protecting islet cells from apoptosis during the donor harvesting process

Publications (1)

Publication Number Publication Date
AR060785A1 true AR060785A1 (en) 2008-07-10

Family

ID=39680975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101971A AR060785A1 (en) 2006-03-20 2007-05-07 METHOD FOR THE PROTECTION OF LANGERHANS ISLANDS CELLS AGAINST APOPTOSIS DURING THE PROCESS OF OBTAINING DONOR CELLS

Country Status (7)

Country Link
EP (1) EP1996707A2 (en)
JP (1) JP5543774B2 (en)
AR (1) AR060785A1 (en)
AU (1) AU2007226878A1 (en)
CA (1) CA2637137A1 (en)
IL (1) IL192388A0 (en)
WO (1) WO2007109677A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536379A (en) * 2007-08-20 2010-12-02 セネスコ テクノロジーズ，インコーポレイティド Use of EIF-5A1 siRNA to protect islet cells from apoptosis and retain their function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
KR20050098954A (en) * 2003-03-05 2005-10-12 세네스코 테크놀로지스 인코포레이티드 Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
NZ544159A (en) * 2003-06-06 2009-04-30 Senesco Technologies Inc Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics

Also Published As

Publication number Publication date
WO2007109677A2 (en) 2007-09-27
AU2007226878A1 (en) 2007-09-27
EP1996707A2 (en) 2008-12-03
IL192388A0 (en) 2008-12-29
CA2637137A1 (en) 2007-09-27
JP2009530418A (en) 2009-08-27
JP5543774B2 (en) 2014-07-09
WO2007109677A3 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
CU24495B1 (en) COMPOUNDS THAT EXPAND HEMATOPOIETIC CELLS AND EX VIVO METHOD TO EXPAND HEMATOPOIETIC CELLS
ME01699B (en) Methods of stimulating liver regeneration
BRPI0617378B8 (en) USE OF AN IL-6 INHIBITOR TO PRODUCE A PHARMACEUTICAL COMPOSITION TO SUPPRESS DAMAGE TO AN ISLE TRANSPLANTATION AFTER ISLE TRANSPLANTATION; AND IMPROVE THE FEASIBILITY OF AN ISLAND IN AN ISLAND TRANSPLANTATION
Tourino et al. Tryptamine and dimethyltryptamine inhibit indoleamine 2, 3 dioxygenase and increase the tumor‐reactive effect of peripheral blood mononuclear cells
ES2530995T3 (en) Tumor suppression using human placental perfusate and intermediate natural killer cells that come from human placenta
BR112016025331A2 (en) antimicrobial compositions
MX370149B (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation.
WO2007130612A3 (en) Method for obtaining and storing multipotent stem cells
CO2021006365A2 (en) Compositions and methods to express factor ix
RU2012105924A (en) DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS
WO2009050742A8 (en) Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method
CO6491042A2 (en) PRODUCTION OF ELEVATED POLIOVIRUS TITLES FOR THE PRODUCTION OF VACCINES
CL2015003599A1 (en) Solution containing theralose and dextran to transplant mammalian cells
RU2013110524A (en) TREATMENT OF DIABETES USING PANCREATIC ENDOCRINE CELLS
BR112018003031A2 (en) clinical formulations
CL2009001479A1 (en) A method of isolating a deglycosylated veratrum alkaloid comprising providing a veratrum plant material, contacting an aqueous solution, and extracting the veratrum plant material with a solvent to provide an extract comprising said alkaloid.
BR112012010750A2 (en) human germ stem cell storage system
BR112019006865A2 (en) Inducible caspases and methods for use
WO2006107850A3 (en) Preventing rejection of transplanted tissue using regulatory t cells
NZ763301A (en) Adaptation of hollow-fiber-based cell culture technology for the manufacturing of neo-islets or exosomes from stem cells
MX2022001322A (en) Antigen-specific t cell banks and methods of making and using the same therapeutically.
NI201100153A (en) METHOD TO MULTIPLY CELL TISSUE FROM JATROPHA CURCAS
CL2015003402A1 (en) Fat, human, pluripotent adult stem cells: isolation, characterization and clinical implications
AR060785A1 (en) METHOD FOR THE PROTECTION OF LANGERHANS ISLANDS CELLS AGAINST APOPTOSIS DURING THE PROCESS OF OBTAINING DONOR CELLS
BR112012026882A2 (en) systems for sowing cells on three-dimensional supports

Legal Events

Date Code Title Description
FA Abandonment or withdrawal